All In Biotech

Drug Trial Radar · NCT07391332

Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 8, 2026

Primary completion

Jul 8, 2029

Study completion Jul 8, 2029

Sponsor

Lead sponsor
Nantes University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The PASSENGER project aims to conduct a pilot feasibility study of the implementation of a randomized clinical trial on psilocybin-assisted psychotherapy for the treatment of gambling disorder. Feasibility will be assessed by estimating the ability to retain participants until the end of the protocol. Other objectives of the study will be to generate preliminary efficacy data, identify clinical factors potentially associated with the intensity of the psychedelic experience (which determines the expected therapeutic effect), and conduct a preliminary assessment of the safety of the treatment under study.

Conditions

  • Gambling Disorder

Interventions

  • Psychotherapy assisted by high-dose psilocybin (25mg or 40mg where appropriate)Drug

    The first session of psilocybin PEX010 administration will use a moderately high dose of psilocybin, i.e., 25 mg. The dose may be increased to 40 mg during the second administration session in the experimental group, depending on the response during the previous session, as assessed by the Mystical Experience Questionnaire-30 (MEQ-30).

  • Psychotherapy assisted by low-dose psilocybin (1 mg)Drug

    The first session of psilocybin PEX010 administration will use a very low dose of 1 mg in the control group. During the second administration session, the dose will be maintained at 1 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Protocol completion rateTime frame: End of study (33 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nantes University Hospital

    Nantes, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.